Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

All That Glitters: Bristol/Merck's Muraglitazar Will Be Pargluva

This article was originally published in The Pink Sheet Daily

Executive Summary

The companies release Phase II and III data for the dual PPAR agonist at the American Diabetes Association annual meeting. Pargluva showed a statistically significant difference in reduction of A1C levels versus Lilly/Takeda's Actos in type 2 diabetes patients in the 24-week Phase III trial.

You may also be interested in...



Bristol's Abatacept, Muraglitazar To Go Before Advisory Committees In September

Orencia (abatacept) for moderately to severely active rheumatoid arthritis will be reviewed by FDA's Arthritis Drugs Advisory Commmittee. Pargluva (muraglitazar) will be considered by FDA's Endocrinologic & Metabolic Drugs Advisory Committee for type II diabetes mellitus.

Bristol's Abatacept, Muraglitazar To Go Before Advisory Committees In September

Orencia (abatacept) for moderately to severely active rheumatoid arthritis will be reviewed by FDA's Arthritis Drugs Advisory Commmittee. Pargluva (muraglitazar) will be considered by FDA's Endocrinologic & Metabolic Drugs Advisory Committee for type II diabetes mellitus.

AstraZeneca Galida NDA Delayed Until 2007 Due To PPAR Safety Concerns

AstraZeneca will delay an NDA filing for its dual PPAR Galida (tesaglitazar) until 2007 in order to gather two years of long-term follow-up data

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel